Background: Lung cancer is the principal cause of cancer-related deaths worldwide. Early detection of lung cancer with screening is indispensable to reduce the high morbidity and mortality rates. Artificial intelligence (AI) is widely utilised in healthcare, including in the assessment of medical images. A growing number of reviews studied the application of AI in lung cancer screening, but no overarching meta-analysis has examined the diagnostic test accuracy (DTA) of AI-based imaging for lung cancer screening.
Objective: To systematically review the DTA of AI-based imaging for lung cancer screening.
Methods: PubMed, EMBASE, Cochrane Library, CINAHL, IEEE Xplore, Web of Science, ACM Digital Library, Scopus, PsycINFO, and ProQuest Dissertations and Theses were searched from inception to date. Studies that were published in English and that evaluated the performance of AI-based imaging for lung cancer screening were included. Two independent reviewers screened titles and abstracts and used the Quality Assessment of Diagnostic Accuracy Studies-2 tool to appraise the quality of selected studies. Grading of Recommendations Assessment, Development, and Evaluation to diagnostic tests was used to assess the certainty of evidence.
Results: Twenty-six studies with 150,721 imaging data were included. Hierarchical summary receiver-operating characteristic model used for meta-analysis demonstrated that the pooled sensitivity for AI-based imaging for lung cancer screening was 94.6 % (95 % CI: 91.4 % to 96.7 %) and specificity was 93.6 % (95 % CI: 88.5 % to 96.6 %). Subgroup analyses revealed that similar results were found among different types of AI, region, data source, and year of publication, but the overall quality of evidence was very low.
Conclusion: AI-based imaging could effectively detect lung cancer and be incorporated into lung cancer screening programs. Further high-quality DTA studies on large lung cancer screening populations are required to validate AI's role in early lung cancer detection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2022.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global research trends and emerging hotspots in nano-drug delivery systems for lung cancer: a comprehensive bibliometric analysis (1998-2024).
Discov Oncol
January 2025
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400010, China.
Purpose: Nano-drug delivery systems (NDDS) have become a promising alternative and adjunctive strategy for lung cancer (LC) treatment. However, comprehensive bibliometric analyses examining global research efforts on NDDS in LC are scarce. This study aims to fill this gap by identifying key research trends, emerging hotspots, and collaboration networks within the field of NDDS and LC.
View Article and Find Full Text PDFDiagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series.
Clin Exp Med
January 2025
Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Lung cancer is one of the major causes of cancer morbidity and mortality. Subtyping of non-small cell lung cancer is necessary owing to different treatment options. This study is to evaluate the value of immunohistochemical expression of glypican-1 in the diagnosis of lung squamous cell carcinoma (SCC).
View Article and Find Full Text PDFEthnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Clin Transl Oncol
January 2025
Federal University of Pará, Belém, Pará, 66073-005, Brazil.
Background: The benefit of treatment with tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR-TKI) for lung adenocarcinoma (ADC), stratified by ethnicity, has not yet been fully elucidated.
Methods: We searched PubMed, Embase, and Cochrane databases for studies that investigated EGFR-TKI for lung ADC. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs).
Retinal Metastasis Secondary to Lung Cancer Treated with Local Photodynamic Therapy and Systemic Nivolumab.
Ophthalmol Retina
January 2025
Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada.
The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer.
Ann Thorac Surg
January 2025
Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Background: The use of local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving, with a preponderance of data supporting the benefits of such therapeutic approaches incorporating pulmonary resection for appropriately selected candidates. However, practices vary widely institutionally and regionally, and evidence-based guidelines are lacking.
Methods: The Society of Thoracic Surgeons assembled a panel of thoracic surgical oncologists to evaluate and synthesize the available evidence regarding the role of pulmonary resection as LCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!